TABLE 3.
Follow-up data
| Unprotected left main stem (n=54)
|
|||
|---|---|---|---|
| Criteria | BMS | DES | P |
| Clinical follow-up | |||
| Clinical follow-up available, n (%) | 37 (97) | 16 (100) | 1.000 |
| Median follow-up time, months (Q1, Q3) | 24 (12, 35) | 22 (15, 38) | 0.457 |
| Overall death rate, n (%) | 10 (26) | 1 (6) | 0.262 |
| Cardiac death within nine months | 6 (16) | 0 (0) | 0.176 |
| Noncardiac death within nine months | 1 (3) | 0 (0) | 1.000 |
| Angiographic follow-up | |||
| Angiographic follow-up available, n (%) | 23 (61) | 13 (81) | 0.209 |
| Angiographic follow-up, months (Q1; Q3) | 7 (4, 22) | 7 (5, 13) | 0.691 |
| Target lesion revascularization rate, n (%) | 7 (18) | 3 (19) | 1.000 |
| Balloon angioplasty | 0 (0) | 0 (0) | – |
| PCI plus DES | 4 (11) | 1 (6) | – |
| PCI plus PTFE-covered stent | 1 (3) | 0 (0) | – |
| CABG operation | 2 (5) | 2 (13) | – |
BMS Bare metal stent; CABG Coronary artery bypass graft; DES Drug-eluting stent; PCI Percutaneous coronary intervention; PTFE Polytetrafluoroethylene; Q1 Twenty-fifth percentile; Q3 Seventy-fifth percentile;